GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE95585 Query DataSets for GSE95585
Status Public on Sep 30, 2017
Title ChIPSeq data from melanoma cancer cell line CHL-1 after Bromodomain and extra terminal (Bet) domain inhibitor treatment
Organism Homo sapiens
Experiment type Genome binding/occupancy profiling by high throughput sequencing
Summary Bromodomain and extra terminal domain (BET) inhibition reduces occupancy of BET-family proteins at promoter and enhancer sites finally leading to genome wide changes in gene transcription.
We used ChIPSeq profiling to investigate genome wide changes in promoter and enhancer occupancy induced by BET inhibitors BAY 1238097 and OTX-015, respectively.
Overall design CHL-1 cells were treated with BAY 1238097 or OTX-015, potent and selective Bromodomain and extra terminal domain (BET) inhibitors, before chromatin immunoprecipitation using antibodies directed against BRD4 and acetylated H3K27.
Contributor(s) Gelato K, Klingbeil O, Lesche R, Haendler B
Citation(s) 28991225
Submission date Mar 01, 2017
Last update date May 15, 2019
Contact name Ralf Lesche
Organization name Bayer Pharma AG
Street address Muellerstr 178
City Berlin
ZIP/Postal code 13342
Country Germany
Platforms (1)
GPL16791 Illumina HiSeq 2500 (Homo sapiens)
Samples (18)
GSM2516776 CHL1_BRD4_D4_01
GSM2516777 CHL1_H3K27Acq_01_BAY
GSM2516778 CHL1_input_D4_01
BioProject PRJNA377564
SRA SRP100943

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE95585_RAW.tar 12.4 Gb (http)(custom) TAR (of BW)
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap